Jill Bueche
Primary Care · Houma, LANPI 1598370991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 34.4% of the total.
Across 86 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$505
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
- Corium, LLC$121
- Neurocrine Biosciences, Inc.$114
- Lilly USA, LLC$106
- Otsuka America Pharmaceutical, Inc.$91
- plus $398 from 13 others
What the payments were for
- Food & beverage$1,469100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $505 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $133 |
| Corium, LLC | 7 | $121 |
| Neurocrine Biosciences, Inc. | 4 | $114 |
| Lilly USA, LLC | 7 | $106 |
| Otsuka America Pharmaceutical, Inc. | 6 | $91 |
| Exact Sciences | 4 | $76 |
| Ironshore Pharmaceuticals Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Vanda Pharmaceuticals Inc. | 1 | $34 |
| Biomarin Pharmaceutical Inc. | 1 | $30 |
| Ardelyx, Inc. | 1 | $27 |
| Abbott | 1 | $25 |
| Dexcom, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Krystal Biotech Inc | 1 | $18 |
| Pfizer | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$1,469 in reported general payments places this provider in the 65th percentile of 106 primary care providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 105 | $118,203 |
| TrulicityDulaglutide | 20 | $28,531 |
| OzempicSemaglutide | 27 | $25,581 |
| JardianceEmpagliflozin | 20 | $23,009 |
| EliquisApixaban | 19 | $16,442 |
| LinzessLinaclotide | 22 | $11,455 |
| JanuviaSitagliptin Phosphate | 11 | $9,661 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,131 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $5,504 |
| Dexlansoprazole DrDexlansoprazole | 11 | $2,496 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 83 | $2,235 |
| Gabapentin | 66 | $988 |
| Diclofenac Sodium | 57 | $940 |
| Omeprazole | 37 | $635 |
| Pregabalin | 35 | $533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $106 | $146,734125 claims |
| Novo NordiskOzempic | $20 | $25,58127 claims |
| Boehringer IngelheimJardiance | $14 | $23,00920 claims |
| PfizerEliquis | $14 | $16,44219 claims |
| AbbVieLinzess | $505 | $11,45522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 106 primary care providers in Louisiana.
Other primary care in Houma
- Eleisa FloydHouma$6K
- Rose CuneoHouma$3K
- Jennifer MilletHouma$3K
- Jennifer VillalobosHouma$2K
- Wendy TaylorShreveport$15K
- Jodi BurasCovington$14K
- Mia Schexnayder-DavisNew Orleans$10K
- Lourdes TorresMonroe$8K
- Danielle WebsterPrairieville$8K
- Alle NorrisCovington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.